Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect?

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 100-106

  Karimi, Morvarid ^a   Moerlein, Stephen M ^a,b   Videen, Tom O ^a,b   Luedtke, Robert R ^c   Taylor, Michelle ^c   Mach, Robert H ^a,b   Perlmutter, Joel S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

D2 like dopamine receptors; D3 dopamine receptor; Dopamine; Dystonia; NMB; PET

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; N METHYL BENPERIDOL F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN 2A RECEPTOR; SPIPERONE; SPIPERONE F 18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DRUG RECEPTOR BINDING; DRUG UPTAKE; FEMALE; FOCAL DYSTONIA; FOCAL HAND DYSTONIA; HUMAN; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR AFFINITY;

ADULT; CORPUS STRIATUM; DYSTONIC DISORDERS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2;

EID: 79951486473     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23401     Document Type: Article

References (71)

1. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998; 78: 1-10.
2. Wooten GF, Trugman JM. The dopamine motor system. Mov Disord 1989; 4(Suppl. 1): S38-S47.
3. Schneider SA, Bhatia KP, Hardy J. Complicated recessive dystonia parkinsonism syndromes. Mov Disord 2009; 24: 490-499.
4. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23: 73-78.
5. Nygaard TG. Dopa-responsive dystonia. Curr Opin Neurol 1995; 8: 310-313.
6. Brancati F, Valente EM, Castori M, et al. Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. J Neurol Neurosurg Psychiatry 2003; 74: 665-666.
7. Playford ED, Fletcher NA, Sawle GV, Marsden CD, Brooks DJ. Striatal [18F]dopa uptake in familial idiopathic dystonia. Brain 1993; 116: 1191-1199.
8. Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, Standaert DG. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 2007; 102: 783-788.
9. Tabbal SD, Mink JW, Antenor JV, Carl JL, Moerlein SM, Perlmutter JS. MPTP-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006; 141: 1281-1287.
10. Perlmutter JS, Stambuk MK, Markham J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 1997; 17: 843-850.
11. Asanuma K, Ma Y, Okulski J, et al. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 2005; 64: 347-349.
12. Garver DL, Davis DM, Dekirmenjian H, Ericksen S, Gosenfeld L, Haraszti J. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacologia 1976; 47: 199-201.
13. Kolbe H, Clow A, Jenner P, Marsden CD. Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors. Neurology 1981; 31: 434-439.
14. Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 1986; 88: 403-419.
15. Perlmutter JS, Tempel LW, Black KJ, Parkinson D, Todd RD. MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia. Neurology 1997; 49: 1432-1438.
16. Perlmutter JS, Moerlein SM, Huang D-R, Todd R. Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding. J Neurosci 1991; 11: 1381-1389.
17. Moerlein SM, Perlmutter JS, Markham J, Welch MJ. In vivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding. J Cereb Blood Flow Metab 1997; 17: 833-845.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
20. Moerlein SM, Banks WR, Parkinson D. Production of fluorine-18 labeled (3-N-methyl)benperidol for PET investigation of cerebral dopaminergic receptor binding. Int J Rad Appl Instrum A 1992; 43: 913-917.
21. Moerlein SM, Perlmutter JS, Cutler PD, Welch MJ. Radiation dosimetry of [18F](N-methyl)benperidol as determined by whole-body PET imaging of primates. Nucl Med Biol 1997; 24: 311-318.
22. Wienhard K, Dalhbom M, Eriksson L, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994; 18: 110-118.
23. Ollinger JM. Model-based scatter correction for fully 3D PET. Phys Med Biol 1996; 41: 153-176.
24. Karimi M, Golchin N, Tabbal SD, et al. Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. Brain 2008; 131: 2710-2719.
25. Talairach J. Co-planar stereotaxic atlas of the human brain. New York: Theime Verlag; 1988.
26. Andersson JL, Sundin A, Valind S. A method for coregistration of PET and MR brain images. J Nucl Med 1995; 36: 1307-1315.
27. Pluim JP, Maintz JB, Viergever MA. Image registration by maximization of combined mutual information and gradient information. IEEE Trans Med Imaging 2000; 19: 809-814.
28. Antenor-Dorsey JA, Markham J, Moerlein SM, Videen TO, Perlmutter JS. Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans. Nucl Med Biol 2008; 35: 335-341.
29. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
30. Luedtke RR, Freeman RA, Boundy VA, Martin MW, Huang Y, Mach RH. Characterization of (125)I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 2000; 38: 438-449.
31. Magar ME. Data analysis in biochemistry and biophysics. New York: Academic Press; 1972. p 93.
32. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
33. Carbon M, Niethammer M, Peng S, et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology 2009; 72: 2097-2103.
34. Perlmutter JS, Stambuk MK, Markham J, et al. Decreased [18F]spiperone binding in putamen in dystonia. In: Fahn S, Marsden CD, DeLong MR, editors. Dystonia 3. Philadelphia: Lippincott-Raven; 1998. p 161-168.
35. Beukers RJ, Booij J, Weisscher N, Zijlstra F, van Amelsvoort TA, Tijssen MA. Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging 2009; 36: 269-274.
36. Berger HJ, van der Werf SP, Horstink CA, Cools AR, Oyen WJ, Horstink MW. Writer's cramp: restoration of striatal D2-binding after successful biofeedback-based senorimotor training. Parkinsonism Relat Disord 2007; 13: 170-173.
37. Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage 2009; 46: 447-458.
38. Xu J, Hassanzadeh B, Chu W, et al. [(3)H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen. Synapse 2010; 64: 449-459.
39. Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985; 108: 463-483.
40. Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology 2002; 59: 445-448.
41. Matsumoto M, Hidaka K, Tada S, Tasaki Y, Yamaguchi T. Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J Neurochem 1996; 66: 915-919.
42. 3 receptor mRNA and binding sites in human brain. Mol Brain Res 1993; 18: 187-192.
43. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999; 20: 60-80.
44. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
45. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-271.
46. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992; 15: 133-139.
47. Beck S, Richardson SP, Shamim EA, Dang N, Schubert M, Hallett M. Short intracortical and surround inhibition are selectively reduced during movement initiation in focal hand dystonia. J Neurosci 2008; 28: 10363-10369.
48. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432.
49. Keefe KA, Gerfen CR. D1-D2 dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression. Neuroscience 1995; 66: 903-913.
50. Sciamanna G, Bonsi P, Tassone A, et al. Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiol Dis 2009; 34: 133-145.
51. Torres-Russotto D, Perlmutter JS. Task-specific dystonias: a review. Ann N Y Acad Sci 2008; 1142: 179-199.
52. Quartarone A, Rizzo V, Terranova C, et al. Abnormal sensorimotor plasticity in organic but not in psychogenic dystonia. Brain 2009; 132(Part 10): 2871-2877.
53. Sanger TD, Merzenich MM. Computational model of the role of sensory disorganization in focal task-specific dystonia. J Neurophysiol 2000; 84: 2458-2464.
54. Pisani A, Centonze D, Bernardi G, Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 2005; 20: 395-402.
55. Horvitz JC. Stimulus-response and response-outcome learning mechanisms in the striatum. Behav Brain Res 2009; 199: 129-140.
56. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypes: a new hypothesis. Trends Neurosci 2000; 23(10 Suppl): S71-S77.
57. Peterson DA, Sejnowski TJ, Poizner H. Convergent evidence for abnormal striatal synaptic plasticity in dystonia. Neurobiol Dis 2010; 37: 558-573.
58. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994; 44: 163-196.
59. Rice ME. Distinct regional differences in dopamine-mediated volume transmission. Prog Brain Res 2000; 125: 277-290.
60. Venton BJ, Michael DJ, Wightman RM. Correlation of local changes in extracellular oxygen and pH that accompany dopaminergic terminal activity in the rat caudate-putamen. J Neurochem 2003; 84: 373-381.
61. Tepper JM, Koos T, Wilson CJ. GABAergic microcircuits in the neostriatum. Trends Neurosci 2004; 27: 662-669.
62. Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron 2008; 60: 543-554.
63. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008; 321: 848-851.
64. Kasim S, Blake BL, Fan X, et al. The role of dopamine receptors in the neurobehavioral syndrome provoked by activation of L-type calcium channels in rodents. Dev Neurosci 2006; 28: 505-517.
65. Nicola SM, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 2000; 23: 185-215.
66. Aizman O, Brismar H, Uhlen P, et al. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci 2000; 3: 226-230.
67. Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43.
68. Heidbreder C. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 2008; 7: 410-421.
69. Fiorentini C, Busi C, Spano P, Missale C. Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Curr Opin Pharmacol 2010; 10: 87-92.
70. Marcellino D, Ferre S, Casado V, et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 2008; 283: 26016-26025.
71. Zapata A, Kivell B, Han Y, et al. Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 2007; 282: 35842-35854.